Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency)

v3.21.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2019 $ 36 $ 3,362,724 $ (8,403,417) $ (5,040,657)
Balance at the beginning (in shares) at Dec. 31, 2019 3,601,521      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation: Options   5,394   5,394
Net loss     (58,098) (58,098)
Balance at the end at Mar. 31, 2020 $ 36 3,368,118 (8,461,515) (5,093,361)
Balance at the end (in shares) at Mar. 31, 2020 3,601,521      
Balance at the beginning at Dec. 31, 2019 $ 36 3,362,724 (8,403,417) (5,040,657)
Balance at the beginning (in shares) at Dec. 31, 2019 3,601,521      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss       (5,727,918)
Balance at the end at Sep. 30, 2020 $ 77 21,723,133 (14,131,335) 7,591,875
Balance at the end (in shares) at Sep. 30, 2020 7,661,300      
Balance at the beginning at Mar. 31, 2020 $ 36 3,368,118 (8,461,515) (5,093,361)
Balance at the beginning (in shares) at Mar. 31, 2020 3,601,521      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation: Options   5,423   5,423
Stock-based compensation: Common stock   3,000   3,000
Stock-based compensation: Common stock (in shares) 1,112      
Forgiveness of accrued expenses by related party   33,738   33,738
Net loss     (1,505,320) (1,505,320)
Balance at the end at Jun. 30, 2020 $ 36 3,410,279 (9,966,835) (6,556,520)
Balance at the end (in shares) at Jun. 30, 2020 3,602,633      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Shares issued upon exercise of warrants, net of issuance costs [1] $ 25 10,605,720   10,605,745
Shares issued upon exercise of warrants, net of issuance costs (in shares) [1] 2,500,000      
Conversion of notes payable and accrued interest into common stock and warrants $ 15 7,304,815   7,304,830
Conversion of notes payable and accrued interest into common stock and warrants (in shares) 1,461,090      
Conversion of notes payable and accrued interest into common stock $ 1 388,143   388,144
Conversion of notes payable and accrued interest into common stock (in shares) 94,223      
Stock-based compensation: Options   5,176   5,176
Stock-based compensation: Common stock   9,000   9,000
Stock-based compensation: Common stock (in shares) 3,334      
Effect of reverse stock split (in shares) 20      
Net loss     (4,164,500) (4,164,500)
Balance at the end at Sep. 30, 2020 $ 77 21,723,133 (14,131,335) 7,591,875
Balance at the end (in shares) at Sep. 30, 2020 7,661,300      
Balance at the beginning at Dec. 31, 2020 $ 118 40,770,504 (16,289,077) 24,481,545
Balance at the beginning (in shares) at Dec. 31, 2020 11,756,109      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Shares issued upon exercise of warrants, net of issuance costs [2] $ 20 9,274,891   $ 9,274,911
Shares issued upon exercise of warrants, net of issuance costs (in shares) 2,047,361 [2]     2,047,361
Stock-based compensation: Options   2,576   $ 2,576
Stock-based compensation: Common stock $ 1 513,102   $ 513,103
Stock-based compensation: Common stock (in shares) 70,040     70,040
Net loss     (1,796,612) $ (1,796,612)
Balance at the end at Mar. 31, 2021 $ 139 50,561,073 (18,085,689) 32,475,523
Balance at the end (in shares) at Mar. 31, 2021 13,873,510      
Balance at the beginning at Dec. 31, 2020 $ 118 40,770,504 (16,289,077) 24,481,545
Balance at the beginning (in shares) at Dec. 31, 2020 11,756,109      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss       (5,810,230)
Balance at the end at Sep. 30, 2021 $ 143 51,827,263 (22,099,307) 29,728,099
Balance at the end (in shares) at Sep. 30, 2021 14,252,886      
Balance at the beginning at Mar. 31, 2021 $ 139 50,561,073 (18,085,689) 32,475,523
Balance at the beginning (in shares) at Mar. 31, 2021 13,873,510      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Shares issued upon exercise of warrants, net of issuance costs [3] $ 1 428,718   $ 428,719
Shares issued upon exercise of warrants, net of issuance costs (in shares) 108,961 [3]     108,961
Common stock issued upon exercise of options   8,361   $ 8,361
Common stock issued upon exercise of options (in shares) 2,815      
Shares issued as partial consideration for intangible asset $ 1 531,999   532,000
Shares issued as partial consideration for intangible asset (in shares) 100,000      
Stock-based compensation: Options   2,509   2,509
Stock-based compensation: Common stock $ 2 27,568   27,570
Stock-based compensation: Common stock (in shares) 167,600      
Net loss $ 0 0 (1,703,005) (1,703,005)
Balance at the end at Jun. 30, 2021 $ 143 51,560,228 (19,788,694) 31,771,677
Balance at the end (in shares) at Jun. 30, 2021 14,252,886      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation: Options   2,533   2,533
Stock-based compensation: Common stock   264,502   264,502
Net loss     (2,310,613) (2,310,613)
Balance at the end at Sep. 30, 2021 $ 143 $ 51,827,263 $ (22,099,307) $ 29,728,099
Balance at the end (in shares) at Sep. 30, 2021 14,252,886      
[1] Includes gross proceeds of $12,503,750, less issuance costs of $1,898,005.
[2] Includes gross proceeds of $9,708,038, less issuance costs of $433,127.
[3] Includes gross proceeds of $460,989, less issuance costs of $32,270.